The nation of Zimbabwe has turned down a substantial American health deal valued at 367 million US dollars (£272m) over five years over Washington's demand for sensitive biological samples.
This move was revealed after a official document dated December was disclosed, which showed President Emmerson Mnangagwa felt the arrangement was "lopsided".
An official spokesperson later explained that the United States was requesting biological samples for research and commercial purposes while was unwilling to share the resulting advantages from any future medical innovations.
"We must now begin the difficult and regrettable task of ending our health aid in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the US had donated over $1.9bn as health assistance to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has called for more dialogue to find a agreement agreeable to both sides so the nation's critical HIV programme can continue.
Broader Background
Zimbabwe's decision comes after a comparable case in neighbouring Kenya, where a high court halted a similar deal with the US following legal challenges were filed about the security of citizens' medical information.
After returning to office recently, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
USAID had managed aid for the American government, but Trump argued its spending was "inefficient" and his government was seeking government-to-government deals to enhance transparency and accountability.
As per statements, Sixteen African countries have so far agreed to these new agreements, constituting over $18.3bn of fresh investment.
Details of the Declined Deal
The money for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this partnership would have delivered significant benefits for Zimbabwean communities, especially the 1.2 million currently on HIV treatment through US-supported initiatives," Tremont said.
However, official spokesman Nick Mangwana said the arrangement was "unequal".
"Our nation was requested to surrender its genetic material and health information over an extended period, with no equivalent promise of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could result from that provided information," Mangwana explained.
"Effectively, our country would supply the raw materials for medical research without any assurance that the final treatments would be accessible to our people should a future health crisis emerge."
National Interest and Global Health
He also said that the US's withdrawal from the global health body and its pursuit of one-on-one health agreements were upending structures already set up via the global organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing system designed to deal with potential pandemics.
"This framework is intended to ensure that when a country provides its samples, the resulting advantages – including medicines and cures – are distributed fairly, not monopolised solely by those with the funds to develop them."
The government's concerns over the US deal "must not be interpreted as opposition to America," he added.
"We are open to ongoing discussions with our US partners on how subsequent co-operation could be designed in a manner that respects the independence and dignity of both nations."
Health Experts Response
A leading public health body said it recognised the government's concerns, but recommended that negotiations need to persist since much of the country's HIV programmes relied on foreign aid.
"Where specific concerns exist, including those involving information security or agreement terms, these can frequently be addressed through detailed discussion and mutually agreed protections," the group commented.
The situation emphasises the ongoing challenges between accepting crucial international aid and safeguarding local interests in an ever more data-driven world.